1666PDTrilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. (23rd October 2018) - Dragnev, K H; Owonikoko, T K; Csoszi, T; Maglakelidze, M; Beck, J T; Domine Gomez, M; Lowczak, A; Fulop, A; Hoyer, R J; Hanna, W; Lowry, P; Aljumaily, R; et al.